28 June 2021 | News
Emtricitabine, Tenofovir Disoproxil Fumarate tablets of strengths 200 mg/300 mg, have received approval from the US FDA
Lupin announced the launch of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, having received approval from the United States Food and Drug Administration (FDA). Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, are the generic equivalent of Truvada Tablets 200 mg/300 mg, of Gilead Sciences, Inc, and indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (RLD: Truvada) had estimated annual sales of $ 2.1 billion in the US (IQVIA MAT March 2021).